Publications by authors named "Han-Fang Cheng"
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have demonstrated significant clinical benefits in progression-free and overall survival. This study investigates the outcomes associated with two kinds of CDK4/6i in patients with hormone receptor (HR)-positive metastatic and relapsed breast cancer to inform real-world evidence of treatment strategies.
Methods: This retrospective study included 340 Taiwanese patients with HR-positive advanced breast cancer from the Taipei Veterans General Hospital, between 2018 and 2023.
Article Synopsis
- The study focuses on the prevalence of genetic mutations in BRCA1, BRCA2, and PALB2 among Taiwanese breast cancer patients as a potential target for cancer therapy using PARP inhibitors.
- Tumor-targeted sequencing was performed on 924 samples from 879 patients, revealing that 14.8% had genetic alterations related to these genes, with notable co-occurrence of mutations among them.
- Of the identified mutations, many were novel, with a significant portion (60.2%) not previously documented, highlighting a need for continued research in genetic profiling for tailored cancer treatments.
Article Synopsis
- This study looked at a type of breast cancer called luminal B1, which has worse outcomes than another type called luminal A.
- Researchers analyzed the genetic information from patients in Taiwan to find targets for possible treatments.
- They found that certain gene changes, especially in PIK3CA, FGFR1, and BRCA1/2, were common in the more serious cases of this cancer.
In this study, we evaluated the concordance of targeted sequencing between paired ctDNA and matched tumor samples from early breast cancers treated with curative intention. Molecular profiling was performed using the Oncomine Comprehensive Assay v3 and the Oncomine Breast cfDNA Assay v2. The liquid biopsy detection rate was 39% (all-stage breast cancers, n = 612).
View Article and Find Full Text PDFPurpose: Invasive lobular cancer (ILC) is the second most common histology type of breast cancer followed by invasive ductal carcinoma (IDC). This study aimed to investigate the characteristic, treatment strategies, and clinical outcomes of ILC based on a national population-based cancer registry.
Methods: This study recruited 2671 ILC and 52,215 IDC patients diagnosed between 2011 and 2017 using the Taiwan Cancer Registry (TCR).
Background: To assess the clinical outcomes and metastatic behavior between de novo versus recurrent human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) based on a single-institution database in Taiwan.
Methods: We retrospectively identified patients diagnosed between January 2000 and December 2017 with de novo stage IV or recurrent HER2-positive MBC. Several variables were recorded in patients with recurrent disease: age at diagnosis, metastatic site, hormone receptor (HR) status, HER2 status, and disease-free interval (DFI).
Exposure to tobacco smoke activates innate and adaptive immune responses that in long-term smokers have been linked to diseases of the lungs, cardiovascular system, joints, and other organs. The destruction of lung tissue that underlies smoking-induced emphysema has been associated with T helper 1 cells that recognize the matrix protein elastin. Factors that result in the development of such autoreactive T cells in smokers remain unknown but are crucial for further understanding the pathogenesis of systemic inflammatory diseases in smokers.
View Article and Find Full Text PDF